Podcast: Adding Combination Therapies to Drug Pipelines
A new podcast featuring author and futurist Jonathan Peck and Nerac Life Sciences Analyst Irene Zajac, examines how combination therapies are taking on considerable importance as pharmaceutical companies adjust their development pipelines.
Download our Complimentary White Paper: “New Perspectives on the Future of Drug Discovery”
See how Nerac’s analysis of patent and non-patent information in bio-pharma gives insights into drug pipeline activity, identifies new growth opportunities and charts an effective plan for success!
Don’t Miss Our Bio-Pharma Marketplace Review
Each month, Nerac bio-pharma analysts share their knowledge and insights as they explore news and trends in technology, intellectual property, health and wellness, and business and industry. Sign up to receive this valuable monthly publication delivered right to your desktop.
Marketplace Review
July-August 2008 Issue:
What this Court Decision Means for Patent Licensing
Restrictions Put on Earning Royalties after the Patented Product Is Sold
The Supreme Court told patent holders that the doctrine of patent exhaustion is more expansive than patent holders had thought―or hoped. This is especially important as technological advancements continue to be made that involve multiple elements, each of which may be separately patentable, being combined into something new. (more)
The World Is Not Waiting for the U.S. to Decide on Regulations
Very few biogeneric drugs have approved in the United States, and few others are on the horizon. Yet they are almost routinely approved and used in the European Union, India and several other countries for the last few years. Why is that and what has to happen so the U.S. can catch up with the rest of the world? (more)
Will “Wait and See” Transition to “Let’s Know Now”?
Even before Vioxx, the Food & Drug Administration had long been criticized for employing a slow, inadequate, unsystematic method of monitoring post-market safety. Months or even years can go by before government agents begin to notice unexpected side effects from approved drugs, and those delays potentially cost lives. That should start to change in the coming years as the FDA’s new Sentinel System is implemented. (more)
Vaccination Changes Bring New Opportunities for Drug Makers and Veterinarians
Until recently, veterinarians and owners commonly administered vaccines to all companion dogs annually for several infectious diseases. In 2005, however, the American Animal Hospital Association’s Canine Vaccine Task Force agreed on a new vaccine protocol based on scientific evidence suggesting that annual vaccinations are unnecessary. What would the financial impact be on veterinarians and vaccine manufacturers? An examination of patent literature since 2006 offers some insight into how pharmaceutical companies have shifted their focus. (more)
Check out last month’s bio-pharma MPR here.